EMA: No biowaivers for NTIDs [Dissolution / BCS / IVIVC]

posted by Relaxation  – Germany, 2020-07-16 08:54 (276 d 15:30 ago) – Posting: # 21707
Views: 1,159

Hello everyone.

Just to complement the answer quickly.
There actually is a product-specific guidance for rivaroxaban. I hope that I do not mix something up, but it currently seems valid.
Its just not considering it as an NTI as the recommended acceptance range is not narrowed in accordance with the basic BE-Guideline.

https://www.ema.europa.eu/en/rivaroxaban-product-specific-bioequivalence-guidance

Note: other authorities see this differently.

Best regards,
Steven.

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 17 (0 registered, 17 guests [including 6 identified bots]).
Forum time: Monday 00:24 UTC (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5